Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Common Stock (NQ:NXL)

4.390 +0.040 (+0.92%)
Streaming Delayed Price Updated: 11:44 AM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,164
Open 4.390
Bid (Size) 4.350 (400)
Ask (Size) 4.680 (100)
Prev. Close 4.350
Today's Range 4.390 - 4.390
52wk Range 4.000 - 60.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
These stocks are moving in today's session ↗
Via Chartmill

Performance

YTD
-74.9%
-74.9%
1 Month
-42.6%
-42.6%
3 Month
-57.3%
-57.3%
6 Month
-58.5%
-58.5%
1 Year
-84.4%
-84.4%

More News

Read More
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Nexalin Technology Announces Reverse Stock Split
From Nexalin Technology, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
RedChip's Biotech Investor Conference Replays Now Available
Via ACCESS Newswire
News headline image
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference
Via ACCESS Newswire
News headline image
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Unusual volume stocks in Friday's session ↗
Via Chartmill
News headline image
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
From Nexalin Technology, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Nexalin Technology, Inc. - Common Stock publicly traded?
Yes, Nexalin Technology, Inc. - Common Stock is publicly traded.
What exchange does Nexalin Technology, Inc. - Common Stock trade on?
Nexalin Technology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nexalin Technology, Inc. - Common Stock?
The ticker symbol for Nexalin Technology, Inc. - Common Stock is NXL on the Nasdaq Stock Market
What is the current price of Nexalin Technology, Inc. - Common Stock?
The current price of Nexalin Technology, Inc. - Common Stock is 4.390
When was Nexalin Technology, Inc. - Common Stock last traded?
The last trade of Nexalin Technology, Inc. - Common Stock was at 09/25/26 11:44 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.